# Pharmacokinetics, Safety and Tolerability of CKD-387 10/500mg BE Phase1

> **NCT04156685** · PHASE1 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 58 (actual)

## Conditions studied

- Type2 Diabetes Mellitus

## Interventions

- **DRUG:** Part A, Reference (D635 10/500mg, Astrazeneca)
- **DRUG:** Part A, Reference (D635 10/500mg, Astrazeneca)
- **DRUG:** Part B, Reference (D635 10/500mg, Astrazeneca)
- **DRUG:** Part B, Reference (D635 10/500mg, Astrazeneca)

## Key facts

- **NCT ID:** NCT04156685
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-06
- **Primary completion:** 2019-08-30
- **Final completion:** 2019-10-02
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2019-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04156685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04156685, "Pharmacokinetics, Safety and Tolerability of CKD-387 10/500mg BE Phase1". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT04156685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*